Health Canada is proposing to give generic drugs manufactured in Canada an earlier place in its regulatory review queue, and the public comment period on the plan closes Friday, Sept. 12, 2026.
The proposal, published as a notice on July 15, would run as a targeted, time-limited pilot covering two categories of generic drug filings: abbreviated new drug submissions and supplemental abbreviated new drug submissions. Under it, Health Canada would treat domestic manufacturing as one additional factor when deciding the order in which submissions are picked up for review, applied after urgent health and safety considerations. The department said the aim is to help prevent and mitigate potential supply disruptions for people in Canada.
The consultation drew coverage Tuesday from the compliance outlet GRIP, which noted the regulator is facing rising submission volumes and mounting pressure on approval timelines. It has attracted almost no attention in Canadian consumer media, which matters because the comment window is open to far more than industry. Health Canada’s consultation page lists patient involvement organizations, health care professionals, academics and interested members of the public among those it wants to hear from, and comments can be sent by email to [email protected] until Friday.
What the pilot would and would not do is worth reading closely, because the notice is more modest than the headline suggests. Health Canada states plainly that prioritization refers only to the order in which eligible submissions are selected for review, and that it does not affect the scientific review, the evidentiary standards, filing dates or the decision itself. There is no new approval pathway and no lowered bar. Any gain would come from a review starting sooner, not from it running faster or ending differently. The department has also not published an estimate of how many submissions would qualify, or how many weeks earlier a qualifying review might begin. That is the central unanswered question for anyone trying to judge whether the pilot would move the needle on shortages at all.
The eligibility rules narrow it further. To qualify, a sponsor would have to attest that the submission involves primary manufacturing in Canada, meaning the core production steps for the finished drug or the active pharmaceutical ingredient. Activities limited to testing, packaging or labelling would not count, according to the notice. That distinction matters in a country where a meaningful share of pharmaceutical operations sits in exactly those later-stage steps, and it suggests the pool of qualifying submissions could be small.
The shortage numbers explain why Ottawa is looking at manufacturing at all. Health Canada’s most recent annual review, covering fiscal 2024-25 and published in January, recorded 2,588 new drug shortage reports, down about 20 per cent from the previous year, with 1,772 reports still active at the close of the period. Twenty-two drugs were designated Tier 3, the department’s category for shortages with the highest potential impact on patients and the health system, and 11 of those remained unresolved at year end. The single largest cause was not demand or shipping. Disruption of the manufacture of the drug accounted for 65 per cent of shortages, against 15 per cent for increased demand and nine per cent for shipping delays.
The consequences are concrete. Controlled release carbamazepine, used to treat epilepsy, nerve pain and bipolar disorders, was in shortage from May 2024 to January 2025 after manufacturing disruptions, and Health Canada permitted the exceptional importation of U.S.-authorized supply to cover the gap. Loxapine injection, used to manage schizophrenia, was short for five months in 2024 for the same reason.
The pilot is also the third federal move this year touching review timelines, following a spring consultation on relying on foreign regulators’ approval decisions and the July launch of a reliance framework starting with pediatric and veterinary drugs. Read together, they describe a regulator trying to manage a workload problem at the same time as a supply problem draws political attention. Health Canada itself frames the pilot as one targeted, interim action within a broader set of measures under consideration across government.
News peg via GRIP (Global Relay Intelligence & Practice). Primary sources: Health Canada’s consultation notice, the consultation page, and Health product shortages in Canada: Fiscal year 2024 to 2025 in review.
